Abstract
IntroductionOptimum doses of secondary prevention cardiac medicines need to be achieved post-ACS to derive evidence-based benefits, including reductions in mortality, hospital readmission and improved symptom control. High intensity statin therapy...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
